ZYNCOR-5 price in UAE

Overview

Welcome to Dwaey, specifically on ZYNCOR-5 Tablets/Film-coated page.
This medicine contains an important and useful components, as it consists of Bisoprolol fumarate.
ZYNCOR-5 is available in the market in concentration 5mg/Tablet and in the form of Tablets/Film-coated.

OMAN PHARMACEUTICAL PRODUCTS is the producer of ZYNCOR-5 and it is imported from OMAN, The most popular alternatives of ZYNCOR-5 are listed downward .

Mode Of Action

Bisoprolol fumarate/hydrochlorothiazide is a fixed-combination tablet that combines a Beta adrenergic receptor blocker, bisoprolol fumarate, and a thiazide diuretic, hydrochlorothiazide. Bisoprolol fumarate, a cardioselective inhibitor of beta(1)-adrenoceptor, has no significant intrinsic sympathomimetic activity or membrane stabilizing activity in its therapeutic dosage; exhibits beta(2)-adrenoceptors inhibition and negative chronotropic effect. Hydrochlorothiazide is a thiazide diuretic that inhibits Na reabsorption in distal renal tubules resulting in increased excretion of Na+ and water, also K+ and H+ ions.

Indication

Hypertension
Congestive heart failure
HTN
Angina pectoris

Precaution

Bronchospastic disease, hyperthyroidism, peripheral vascular disease, undergoing anaesthesia. Monitor blood glucose regularly. May mask symptoms of hypoglycaemia. Elderly. Gradual withdrawal is advised. Lactation: excreted in breast milk, use caution

Side Effects

1-10% Bisoprolol fumarate Arthralgia (3%)
asthenia (2%)
cough (3%)
diarrhea (4%)
dizziness (10%)
dry mouth (1%)
dyspnea (2%)
fatigue (8%)
headache (11%)
hypoaesthesia (2%)
insomnia (3%)
nausea (2%)
peripheral edema (4%)
pharyngitis (2%)
rhinitis (4%)
sinusitis (2%)
upper respiratory infection (5%)
vomiting (2% ) Hydrochlorothiazide Anorexia
Epigastric distress
Hypokalemia
Hypotension
Orthostatic hypotension
Phototoxicity Frequency Not Defined Bisoprolol fumarate Aggravate CHF
cold extremeties
decrease HDL
depression
hypotension
increase bronchospasm
increase triglycerides
mask symptoms of hypoglycemia
muscle & joint pain Hydrochlorothiazide Agranulocytosis
anaphylaxis
anemia
Confusion
erythema multiforme skin reactions including Stevens-Johnson syndrome Exfoliative dermatitis including toxic epidermal necrolysis
Hypomagnesemia
hyponatremia
hypochloremia
dizziness
fatigue
headache
hypercalcemia
hyperuricemia
hyperglycemia
hyperlipidemia
hypercholesterolemia
muscle weakness or cramps
nausea
purpura
rash
vertigo
vomiting Potentially Fatal: AV block
bradycardia. Rare but may occur in patients with preexisting cardiac disease. Includes severe bronchospasm
hypoglycaemia
hypotension
orthostatic hypotension
bradyarrhythmias. 'Rebound phenomenon' leading to unstable angina or MI on sudden withdrawal.

Contra indication

Low cardiac output and uncompensated cardiac failure; sinus bradycardia, 1st ° heart block, cardiogenic shock, bronchospasm; severe haemorrhage. Pregnancy.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Bisoprolol : May potentiate AV conduction time and may increase negative inotropic effect w/ class I antiarrhythmic drugs (e.g. quinidine, disopyramide, propafenone). Concomitant catecholamine-depleting drugs (e.g. reserpine, guanethidine) may produce excessive sympathetic activity. May exacerbate rebound HTN upon discontinuance of clonidine treatment. Increased risk of bradycardia w/ digitalis glycosides. Reduced hypotensive effect w/ NSAIDs. Hydrochlorothiazide: Increases toxicity of lithium. May potentiate orthostatic hypotension w/ barbiturates and narcotics. Enhanced neuromuscular blocking action of competitive neuromuscular blockers (e.g. atracurium). Increased hypokalaemic effect w/ corticosteroids, corticotropin, ?2 agonists (e.g. salbutamol). Additive effect w/ other antihypertensives. Potentiation of orthostatic hypotension w/ barbiturates or opioids. Reduced antihypertensive effect by drugs that cause fluid retention (e.g. corticosteroids, NSAIDs, carbenoxolone). Enhanced nephrotoxicity of NSAIDs. Reduced therapeutic effect of antidiabetics.